For research use only. Not for use in humans.

Anti-ADAM9 (Imgc936)

Synonyms: MDC9, MLTNG

Anti-ADAM9 (Imgc936) is a humanized antibody targeting the ADAM metallopeptidase domain 9 (ADAM9). It is a therapeutic candidate for the treatment of various cancers including non-small cell lung, pancreatic, gastric, breast, ovarian, and colorectal cancer. MW :147.66 KD.

Anti-ADAM9 (Imgc936)

Quality Control

Batch: A317101 Purity: 99% Protein concentration: 6.98mg/ml Endotoxin Level: <1EU/mg
99

Mechanism of Action

Description
Anti-ADAM9 (Imgc936) is a humanized antibody targeting the ADAM metallopeptidase domain 9 (ADAM9). It is a therapeutic candidate for the treatment of various cancers including non-small cell lung, pancreatic, gastric, breast, ovarian, and colorectal cancer. MW :147.66 KD.
References

Product Details

CAS No. 2642078-62-2
Isotype Human IgG1
Source CHO
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)
Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04622774 COMPLETED Drug: IMGC936 Advanced Solid Tumor ImmunoGen, Inc. 2020-10-29 PHASE1; PHASE2

(data from https://clinicaltrials.gov, updated on 2025-01-15)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.